/BXRXQ

BXRXQ Stock - Baudax Bio, Inc.

Q: What is the analyst price target for BXRXQ?

Analyst price target information is not currently available for BXRXQ.

Q: What is BXRXQ's market cap?

Market capitalization information is not currently available for BXRXQ.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BXRXQ

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-11.87

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$1.27M	$1.08M	$493,000	N/A	N/A
Gross Profit	$-5,740,000	$-1,365,000	$-1,239,000	N/A	N/A
Gross Margin	-452.3%	-126.4%	-251.3%	N/A	N/A
Operating Income	$-56,813,000	$-19,006,000	$-74,786,000	$-32,519,000	$-73,535,000
Net Income	$-58,795,000	$-19,769,000	$-76,100,000	$-32,557,000	$-73,667,000
Net Margin	-4633.2%	-1830.5%	-15436.1%	N/A	N/A
EPS	$-177.30	$-361.16	$-5714.80	$-4872.07	$-11361.35

Company Overview

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.

Visit Website

Earnings History & Surprises

BXRXQ

Beat Rate

80%

Last 5 quarters

Avg Surprise

+28.0%

EPS vs Estimate

Beats / Misses

4/1

Last 12 quarters

Latest EPS

$-1.49

Q3 2023

EPS Surprise History

Q3 22

+45.5%

$-27.67vs$-50.80

Q4 22

+25.9%

$-15.71vs$-21.20

Q1 23

+56.5%

$-4.25vs$-9.76

Q2 23

-14.6%

$4.91vs$5.75

Q3 23

+27.0%

$-1.49vs$-2.04

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2025	Feb 11, 2025	—	—	—	—
Q4 2024	Nov 15, 2024	—	—	—	—
Q3 2024	Aug 16, 2024	$-0.09	—	—	—
Q2 2024	May 16, 2024	$-0.12	—	—	—
Q1 2024	Feb 14, 2024	$-0.12	—	—	—
Q4 2023	Nov 20, 2023	$-0.53	—	—	—
Q3 2023	Aug 16, 2023	$-2.04	$-1.49	+27.0%	✓ BEAT
Q2 2023	May 12, 2023	$5.75	$4.91	-14.6%	✗ MISS
Q1 2023	Feb 23, 2023	$-9.76	$-4.25	+56.5%	✓ BEAT
Q4 2022	Nov 8, 2022	$-21.20	$-15.71	+25.9%	✓ BEAT
Q3 2022	Aug 11, 2022	$-50.80	$-27.67	+45.5%	✓ BEAT